Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

It's Fusion As Jazz Pharmaceuticals, Azur Pharma Reach Merger Agreement

This article was originally published in The Pink Sheet Daily

Executive Summary

The maker of narcolepsy drug Xyrem gets a portfolio of CNS and women's health drugs while moving its headquarters to Ireland, saving millions on taxes.
Advertisement

Related Content

Elan’s Saga Comes To A Close With Perrigo’s $8.6 Billion Bid
Elan’s Saga Comes To A Close With Perrigo’s $8.6 Billion Bid
Jazz And Concert In Tune On Xyrem
Jazz Enters Oncology Market With EUSA Acquisition
Narrower Indication, New Studies Are Likely Riffs For Jazz Fibromyalgia Drug
Narrower Indication, New Studies Are Likely Riffs For Jazz Fibromyalgia Drug
CEO Quits Troubled Jazz, Hits The Road With Folk Singer Wife
Jazz Pharmaceuticals IPO Will Fund Luvox CR Commercialization

Topics

Advertisement
UsernamePublicRestriction

Register

PS072797

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel